64 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- Novartis (Switzerland)CH6 papers
- Medical University of ViennaAT3 papers
- Statistics AustriaAT3 papers
- Novartis (China)CN2 papers
- University Hospital MagdeburgDE2 papers
- AstraZeneca (Sweden)SE1 paper
- Berry & Associates (United States)US1 paper
- Berry Consultants, LLC (United States)US1 paper
- Charité - Universitätsmedizin BerlinDE1 paper
- Constellium (United Kingdom)GB1 paper
- Franklin UniversityUS1 paper
- Institute of Neuroimmunology and Multiple SclerosisDE1 paper
Showing 2025Show all
2 papers · 1 filter
stat.ME2025
Inverse Probability Weighting for Recurrent Event Models
Jiren Sun, Tobias Mutze, Richard Cook +1
Recurrent events are common and important clinical trial endpoints in many disease areas, e.g., cardiovascular hospitalizations in heart failure, relapses in multiple sclerosis, or…
stat.AP2025★ 3 cited
Using Individualized Treatment Effects to Assess Treatment Effect Heterogeneity
Konstantinos Sechidis, Cong Zhang, Sophie Sun +3
Assessing treatment effect heterogeneity (TEH) in clinical trials is crucial, as it provides insights into the variability of treatment responses among patients, influencing import…